research use only
Cat.No.S8535
| Related Targets | CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR |
|---|---|
| Other CFTR Inhibitors | Tezacaftor (VX-661) VX-445 (Elexacaftor) Vanzacaftor (VX-121) CFTRinh-172 GLPG1837 FDL169 GlyH-101 IOWH032 PPQ-102 Nesolicaftor (PTI-428) |
|
In vitro |
DMSO
: 100 mg/mL
(178.74 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 559.46 | Formula | C28H21F4NO7 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1918143-53-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | GLPG2222 | Smiles | C1CC1(C2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4CC(OC5=C4C=CC(=C5)OC(F)F)C6=CC=C(C=C6)C(=O)O | ||
| Targets/IC50/Ki |
CFTR
|
|---|---|
| In vitro |
Galicaftor (ABBV-2222) exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR with an EC50 <10 nM. It promotes maturation of F508delCFTR, stabilizes nucleotide binding domain 1 - membrane spanning domain interface, and corrects F508delCFTR through action on membrane spanning domain 1. |
| In vivo |
Pharmacokinetic tests performed in rats on Galicaftor (ABBV-2222; GLPG-2222; 1 mg/kg, i.v.; 1 mg/kg, p.o.) showed that for this compound, T1/2 is 2.7 hours (i.v.) and for intragastric administration, the bioavailability (%F) is 74%. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.